manufacture and market Clarithromycin XL 1000 mg tablets.-Ranbaxy in alliance with Novavax to step in to biotech sector-Ranbaxy Laboratories Ltd enters into collaborative agreement withNational Chemical Laboratories, Pune and Department of Science &Technology in the area of New Drug Discovery.- On May 24, 2005 launches its approved generic formulation ofClarithromycin immediate release (IR) tablets, 250 mg and 500 mg, inthe US markets.-Ranbaxy's Joint Venture with Nippon Chemiphar Ltd launches Vogseal0.2mg & 0.3mg tablets for Diabetes-Ranbaxy sets up additional manufacturing facility in Malaysia-Ranbaxy opens third state of the art R&D facility on Gurgaon campus-Company has splits its Face value of Shares from Rs 10 to Rs 52006-Ranbaxy Laboratories enters into a strategic alliance with Zenotech-Ranbaxy ties up with Ipca to tap US market-Ranbaxy signs licensing agreement with Swiss Company Debiopharm, forNCE Drug in the Gastroenterology Segment-Ranbaxy signs licensing agreement with Swiss Company Debiopharm, forNCE Drug in the Gastroenterology Segment.
-Ranbaxy Appoints Atul Sobti as COO.-Ranbaxy Laboratories Ltd has announced that the Company has enteredinto a collaborative agreement with the Department of Science &Technology (DST), Government of India, New Delhi, in the area of NewDrug Discovery Research (NDDR).-Ranbaxy granted final USFDA approval to Market Simvastatin 5, 10, 20& 40 MG Tablets.2007-Ranbaxy Laboratories Ltd and GlaxosmithKline (GSK) on February 06,2007 have signed a new multiyear R&D agreement that modifies andexpands the terms of their strategic alliance established in 2003 toprovide the Company expanded drug-development responsibilities andfurther financial opportunities.- Ranbaxy unveils asthma inhalation capsules.- Ranbaxy Laboratories Ltd has received final approval from the U.S.Food and Drug Administration (FDA) to manufacture and marketAmlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg(base).- Ranbaxy Laboratories Ltd on August 22, 2007 has the launch ofRoliflo OD (combination of Tamsulosin and Tolterodine) brand in theIndian market for the management of bladder outlet obstruction withconcomitant overactive bladder, a chronic urological disorder. Thisis a Novel Drug Delivery System (NDDS) product which is beingintroduced for the first time in India.2008
-Ranbaxy Laboratories on July 28 said it has launched the genericversion of Omeprazole capsules, used in the treatment of acid relateddiseases in the US healthcare system.2009- Canada approves Ranbaxy's anti-hypertension drug- Daiichi launched Ranbaxy drugs in Japan-Ranbaxy subsidiary makes a deal with German health insurer- Ranbaxy launched Daiichi Sankyo's innovative antihypertensivedrugs2010- Ranbaxy Laboratories Limited (Ranbaxy) has launched a New ChemicalEntity (NCE), Lulifin (Luliconazole), in the Indian Dermatologymarket. This follows a strategic in-licensing agreement with SummitPharmaceuticals International Corporation, Japan (SPI) allowingRanbaxy, exclusive marketing rights, for India, 7'he introduction ofthis NCE, significantly strengthens Ranbaxy's presence in theDermatological segment,- Ranbaxy Laboratories has entered into an agreement with US-basedPfenex Inc for developing biosimilars. Biosimilars are drugs which